PL438696A1 - Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie jak i sposoby ich otrzymywania - Google Patents

Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie jak i sposoby ich otrzymywania

Info

Publication number
PL438696A1
PL438696A1 PL438696A PL43869621A PL438696A1 PL 438696 A1 PL438696 A1 PL 438696A1 PL 438696 A PL438696 A PL 438696A PL 43869621 A PL43869621 A PL 43869621A PL 438696 A1 PL438696 A1 PL 438696A1
Authority
PL
Poland
Prior art keywords
preparation
compounds
well
modified
composition containing
Prior art date
Application number
PL438696A
Other languages
English (en)
Other versions
PL246999B1 (pl
Inventor
Dominika CZERWONKA
Julia Krzywik
Tomasz Sobierajski
Greta Klejborska
Małgorzata Ulrich
Witold MOZGA
Adam Huczyński
Przemysław Pilaszek
Original Assignee
Fileclo Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fileclo Spółka Z Ograniczoną Odpowiedzialnością filed Critical Fileclo Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL438696A priority Critical patent/PL246999B1/pl
Priority to CA3226742A priority patent/CA3226742A1/en
Priority to JP2024504177A priority patent/JP2024527891A/ja
Priority to PCT/EP2022/072050 priority patent/WO2023012323A1/en
Priority to KR1020247003940A priority patent/KR20240070502A/ko
Priority to EP22764330.1A priority patent/EP4380939A1/en
Priority to CN202280054762.2A priority patent/CN118103377A/zh
Priority to EP24189896.4A priority patent/EP4556480A1/en
Priority to US18/681,141 priority patent/US20240294541A1/en
Priority to AU2022322025A priority patent/AU2022322025A1/en
Publication of PL438696A1 publication Critical patent/PL438696A1/pl
Publication of PL246999B1 publication Critical patent/PL246999B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku są związki stanowiące C20-N-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, jak również ich zastosowanie jako leku zwłaszcza jako środka przeciwnowotworowego. Przedmiotem wynalazku jest także sposób otrzymywania produktów pośrednich w sposobie otrzymywania modyfikowanych w pozycji C20 pochodnych salinomycyny jak i produkty pośrednie.
PL438696A 2021-08-05 2021-08-05 Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie PL246999B1 (pl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL438696A PL246999B1 (pl) 2021-08-05 2021-08-05 Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie
CA3226742A CA3226742A1 (en) 2021-08-05 2022-08-05 Compounds constituting c20-modified salinomycin derivatives, a method for obtaining the same, a composition containing the same and a use of said compounds
JP2024504177A JP2024527891A (ja) 2021-08-05 2022-08-05 Ｃ２０修飾サリノマイシン誘導体を構成する化合物、これを取得するための方法、これを含有する組成物、及び上記化合物の使用
PCT/EP2022/072050 WO2023012323A1 (en) 2021-08-05 2022-08-05 Compounds constituting c20-modified salinomycin derivatives, a method for obtaining the same, a composition containing the same and a use of said compounds
KR1020247003940A KR20240070502A (ko) 2021-08-05 2022-08-05 C20-변형된 살리노마이신 유도체를 구성하는 화합물, 이를 얻는 방법, 이를 포함하는 조성물 및 상기 화합물의 용도
EP22764330.1A EP4380939A1 (en) 2021-08-05 2022-08-05 Compounds constituting c20-modified salinomycin derivatives, a method for obtaining the same, a composition containing the same and a use of said compounds
CN202280054762.2A CN118103377A (zh) 2021-08-05 2022-08-05 构成c20修饰盐霉素衍生物的化合物、获得该化合物的方法、含该化合物的组合物和所述化合物的用途
EP24189896.4A EP4556480A1 (en) 2021-08-05 2022-08-05 Compounds constituting c20-modified salinomycin derivatives, a method for obtaining the same, a composition containing the same and a use of said compounds
US18/681,141 US20240294541A1 (en) 2021-08-05 2022-08-05 Compounds constituting c20-modified salinomycin derivatives, a method for obtaining the same, a composition containing the same and a use of said compounds
AU2022322025A AU2022322025A1 (en) 2021-08-05 2022-08-05 Compounds constituting c20-modified salinomycin derivatives, a method for obtaining the same, a composition containing the same and a use of said compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438696A PL246999B1 (pl) 2021-08-05 2021-08-05 Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie

Publications (2)

Publication Number Publication Date
PL438696A1 true PL438696A1 (pl) 2023-02-06
PL246999B1 PL246999B1 (pl) 2025-04-22

Family

ID=83188403

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438696A PL246999B1 (pl) 2021-08-05 2021-08-05 Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie

Country Status (9)

Country Link
US (1) US20240294541A1 (pl)
EP (2) EP4380939A1 (pl)
JP (1) JP2024527891A (pl)
KR (1) KR20240070502A (pl)
CN (1) CN118103377A (pl)
AU (1) AU2022322025A1 (pl)
CA (1) CA3226742A1 (pl)
PL (1) PL246999B1 (pl)
WO (1) WO2023012323A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL242212B1 (pl) * 2020-02-07 2023-01-30 Fileclo Spolka Z Ograniczona Odpowiedzialnoscia Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz sposób otrzymywania produktu pośredniego
CN120398907A (zh) * 2024-01-31 2025-08-01 南京安吉生物科技有限公司 盐霉素衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287298B2 (en) * 2014-09-12 2019-05-14 Centre National De La Recherche Scientifique (Cnrs) Nitrogen-containing analogs of salinomycin, synthesis and use against cancer stem cells and malaria
PL242212B1 (pl) * 2020-02-07 2023-01-30 Fileclo Spolka Z Ograniczona Odpowiedzialnoscia Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz sposób otrzymywania produktu pośredniego

Also Published As

Publication number Publication date
EP4380939A1 (en) 2024-06-12
CA3226742A1 (en) 2023-02-09
WO2023012323A1 (en) 2023-02-09
JP2024527891A (ja) 2024-07-26
CN118103377A (zh) 2024-05-28
EP4556480A1 (en) 2025-05-21
PL246999B1 (pl) 2025-04-22
AU2022322025A1 (en) 2024-02-22
US20240294541A1 (en) 2024-09-05
KR20240070502A (ko) 2024-05-21

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
CL2021002995A1 (es) (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
PH12021551065A1 (en) Fused ring compounds
CR20240238A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)
ECSP22050936A (es) Compuestos tric?clicos sustituidos
BR112021022897A2 (pt) Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX2021003655A (es) Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
SA522431304B1 (ar) عمليات تحضير اللاسميديتان وملح الأسيتات منه
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
CY1118858T1 (el) Νεα παραγωγα πυριμιδινης, παρασκευη αυτων και φαρμακευτικη χρηση αυτων ως αναστολεων φωσφορυλιωσης ακτ(ρκβ)
CY1125323T1 (el) ΚΥΚΛΙΚΑ ΠΑΡΑΓΩΓΑ ΑΙΘΕΡΑ ΤΟΥ ΠΥΡΑΖOΛO[1,5- a]ΠΥΡΙΜΙΔΙΝO-3-ΚΑΡΒOΞΥΑΜΙΔΙOΥ
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
CL2021003228A1 (es) Compuestos tricíclicos y su uso
PL438696A1 (pl) Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie jak i sposoby ich otrzymywania
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.
EA201792234A1 (ru) Новые соединения пиридиния
PH12022551810A1 (en) Protein-antiviral compound conjugates
PY1987737A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias